COVID-19 Forces Rethinking of Automotive Manufacturing Processes, Uetz Says
19 October 2020
Partner Ann Marie Uetz was quoted in an Automotive News article, “Did COVID poke hole in just-in-time practices?” about whether the coronavirus pandemic has prompted a reconsideration of automakers’ preference for just-in-time production practices.
Uetz said Foley’s recent survey of nearly 150 manufacturing executives found that nearly two-thirds of respondents believe the pandemic will result in a shift away from the just-in-time model and a greater use of warehousing to protect manufacturers from the disruptions still threatening to bring down supply chains and assembly plants.
According to Uetz, the emerging thinking is that a choice has to be made between continuing to operate as inexpensively as possible or taking new precautions to be more resilient – even if it means accepting added costs. “Is resiliency in the supply chain most important, or is cost more important?” she asked. “How do you weigh those against each other?”
(Subscription required.)
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”